Hugh Watson

Translational Medicine Head

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Hugh Watson is the Head of Translational Medicine at Evotec ID in Lyon, France. His research focuses on infectious diseases, particularly chikungunya and hepatitis delta virus, utilizing innovative mathematical modeling and clinical trials. He has contributed to numerous publications that explore patient outcomes, treatment efficacy, and health-related quality of life in chronic conditions.

Articles (13)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (4)

Henning Grønbæk

Aarhus University

DENMARK

View details

Peter Jepsen

Aarhus University

DENMARK

View details

Rasmus Gantzel

Aarhus University

DENMARK

View details

Justin Julander

Research Professor

Utah State University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hugh Watson

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Global ultrasound synovitis scores reflect symptom severity and patient outcomes in chronic chikungunya disease

Viral Kinetics During Acute Chikungunya Virus Infection: Insights Into Potential Role of Monoclonal Antibodies in Viral Clearance and Prophylaxis Using Mathematical Modeling

Delta in Denmark: prevalence of hepatitis delta virus infection

Randomized clinical trial on safety of the natriuretic peptide ularitide as treatment of refractory cirrhotic ascites

Non-Selective Beta-Blockers and Risk of Sepsis in Patients with Cirrhosis and Ascites: Results from a Large Observational Study

Development and validation of the Cirrhotic Ascites Severity model—A patient‐reported outcome‐based model to predict 1‐year mortality

Therapeutic and prophylactic treatment with a virus-specific antibody is highly effective in rodent models of Chikungunya infection and disease

Household clustering supports a novel chemoprophylaxis trial design for a mosquito-borne viral disease

Determinants of Health-Related Quality of Life in Chronic Chikungunya Disease in Guadeloupe

Arthralgia resolution rate following chikungunya virus infection

Tender and swollen joint counts are poorly associated with disability in chikungunya arthritis compared to rheumatoid arthritis

Musculoskeletal stiffness is common in healthy adults and increases with age

Chronic Joint Pain 3 Years after Chikungunya Virus Infection Largely Characterized by Relapsing-remitting Symptoms

Collaborators (4)

Henning Grønbæk

Peter Jepsen

Rasmus Gantzel

Justin Julander

Make your next move.